Hepatitis E infection with a benign course during vedolizumab treatment for Crohn's disease: A case report: Hepatitis E during vedolizumab therapy in IBD

Autor:	Goetgebuer, R. L., Masclee, G. M. C., van der Eijk, A. A., van der Woude, C. J., de Man, R. A., de Vries, A. C.
Přispěvatelé:	Gastroenterology and Hepatology
Jazyk:	angličtina
Rok vydání:	2022
Předmět:	Crohn's disease IBD Vedolizumab Hepatitis E
Zdroj:	Clinics and research in hepatology and gastroenterology, 46(7):101948. Elsevier Masson
ISSN:	2210-7401
Popis:	We present a 49 year old female patient with Crohn's disease (CD) in remission on vedolizumab therapy who experienced a symptomatic, though benign, course of acute hepatitis E. Routine blood tests showed substantial elevation of liver enzymes and polymerase chain reaction (PCR) testing confirmed hepatitis E virus (HEV) infection. Vedolizumab therapy was paused, liver enzymes improved three weeks after infection and normalized after six months. The patient recovered completely from mild symptoms. This case shows that hepatitis E is a potential cause of acute hepatitis during vedolizumab therapy, and in this case the infection has run a benign course.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=narcis______::e6d9b406b8658ff8a8de57ca98def165 https://pure.amc.nl/en/publications/hepatitis-e-infection-with-a-benign-course-during-vedolizumab-treatment-for-crohns-disease(01ee23d5-e682-4491-9c3e-6ff2cf018ceb).html Zobrazit plný text záznamu Full Text from ScienceDirect